How to buy ADiTx Therapeutics stock

ADiTx Therapeutics, Inc is a biotechnology business based in the US. ADiTx Therapeutics shares (ADTX) are listed on the NASDAQ and all prices are listed in US Dollars. ADiTx Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of USD$40.7 million.

How to buy shares in ADiTx Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ADiTx Therapeutics. Find the stock by name or ticker symbol: ADTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ADiTx Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ADiTx Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ADiTx Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ADiTx Therapeutics share price

Use our graph to track the performance of ADTX stocks over time.

ADiTx Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$1.655 - USD$7.08
50-day moving average	USD$2.9906
200-day moving average	USD$2.5812
Wall St. target price	USD$14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.6019

Buy ADiTx Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ADiTx Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ADiTx Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADiTx Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-83.89%
Return on equity TTM	-224.27%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$40.7 million

TTM: trailing 12 months

Shorting ADiTx Therapeutics shares

There are currently 350,055 ADiTx Therapeutics shares held short by investors – that's known as ADiTx Therapeutics's "short interest". This figure is 16.8% down from 420,805 last month.

There are a few different ways that this level of interest in shorting ADiTx Therapeutics shares can be evaluated.

ADiTx Therapeutics's "short interest ratio" (SIR)

ADiTx Therapeutics's "short interest ratio" (SIR) is the quantity of ADiTx Therapeutics shares currently shorted divided by the average quantity of ADiTx Therapeutics shares traded daily (recently around 372398.93617021). ADiTx Therapeutics's SIR currently stands at 0.94. In other words for every 100,000 ADiTx Therapeutics shares traded daily on the market, roughly 940 shares are currently held short.

However ADiTx Therapeutics's short interest can also be evaluated against the total number of ADiTx Therapeutics shares, or, against the total number of tradable ADiTx Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADiTx Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ADiTx Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0282% of the tradable shares (for every 100,000 tradable ADiTx Therapeutics shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ADiTx Therapeutics.

Find out more about how you can short ADiTx Therapeutics stock.

ADiTx Therapeutics share dividends

We're not expecting ADiTx Therapeutics to pay a dividend over the next 12 months.

ADiTx Therapeutics overview

ADiTx Therapeutics, Inc. , a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Frequently asked questions

• What percentage of ADiTx Therapeutics is owned by insiders or institutions?

  Currently 14.137% of ADiTx Therapeutics shares are held by insiders and 6.405% by institutions.

• How many people work for ADiTx Therapeutics?

  Latest data suggests 43 work at ADiTx Therapeutics.

• When does the fiscal year end for ADiTx Therapeutics?

  ADiTx Therapeutics's fiscal year ends in December.

• Where is ADiTx Therapeutics based?

  ADiTx Therapeutics's address is: 2569 Wyandotte Street, Mountain View, CA, United States, 94043

• What is ADiTx Therapeutics's ISIN number?

  ADiTx Therapeutics's international securities identification number is: US0070251097